<?xml version='1.0' encoding='utf-8'?>
<document id="23137766"><sentence text="Clinical management of drug-drug interactions in HCV therapy: challenges and solutions." /><sentence text="Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other co-morbidities" /><sentence text=" Drug-drug interactions associated with this polypharmacy are relatively new to the field of HCV pharmacotherapy" /><sentence text=" With the advent of the direct-acting antivirals telaprevir and boceprevir, which are both substrates and inhibitors of the cytochrome P450 (CYP) 3A iso-enzyme, knowledge and awareness of drug-drug interactions have become a cornerstone in the evaluation of patients starting and continuing HCV combination therapy"><entity charOffset="49-59" id="DDI-PubMed.23137766.s4.e0" text="telaprevir" /><entity charOffset="64-74" id="DDI-PubMed.23137766.s4.e1" text="boceprevir" /><pair ddi="false" e1="DDI-PubMed.23137766.s4.e0" e2="DDI-PubMed.23137766.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23137766.s4.e0" e2="DDI-PubMed.23137766.s4.e1" /></sentence><sentence text=" In our opinion, an overview of conducted drug-drug interaction studies and a list of contraindicated medications is not enough for the clinical management of these drug-drug interactions" /><sentence text=" Knowledge of pharmacokinetic profiles and concentration-effect relationships is key for the interpretation of these data, and insight into how to manage these interactions (e" /><sentence text="g" /><sentence text=", dose adjustments, safe alternatives and therapeutic drug monitoring) is of equal importance" /><sentence text=" This review provides a practical overview of the safe and effective management of these clinical challenges" /><sentence text="" /></document>